Screener
Regeneron Pharmaceuticals REGN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $41,730.6 | $40,558.7 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,159.3 | $939.0 |
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
| Finance lease liabilities | 720.0 | — |
| Deferred revenue | 684.8 | 553.0 |
| Total current liabilities | 5,530.6 | 4,368.4 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's accounts payable?
- Regeneron Pharmaceuticals (REGN) reported accounts payable of $1.16B in Q2 2026.
- How has Regeneron Pharmaceuticals's accounts payable changed year-over-year?
- Regeneron Pharmaceuticals's accounts payable increased by 60.1% year-over-year, from $723.9M to $1.16B.
- What is the long-term trend for Regeneron Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's accounts payable has grown at a 14.6% compound annual growth rate (CAGR), from $475.5M to $939M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Regeneron Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude